{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-3064"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-3064","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Development and in vitro characterization of 5-Fluorouracil–loaded PLGA nanoparticles for controlled drug delivery","abstract":"Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive metabolic disorder characterized by excessive lipid accumulation in hepatocytes and chronic inflammation. Nanoparticle-based drug delivery systems offer a promising strategy to enhance therapeutic efficacy while minimizing systemic toxicity. The objective of this study is to formulate and characterize 5-FU–loaded PLGA nanoparticles and evaluate their in vitro performance. 5-FU–loaded PLGA nanoparticles were prepared using the double emulsion solvent evaporation method. The nanoparticles were characterized by particle size, polydispersity index, zeta potential and SEM. Drug encapsulation efficiency, loading capacity and in vitro drug release studies were conducted. The formulated nanoparticles exhibited sizes within the nanoscale range with irregular morphology and successful incorporation of 5-FU within the PLGA matrix. The successful formulation and characterization of 5-FU–loaded PLGA nanoparticles highlight their potential as a controlled drug delivery system. These findings provide a foundation for future studies involving biological evaluation and targeted therapeutic applications.","abstract_html":"Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive metabolic disorder characterized by excessive lipid accumulation in hepatocytes and chronic inflammation. Nanoparticle-based drug delivery systems offer a promising strategy to enhance therapeutic efficacy while minimizing systemic toxicity. The objective of this study is to formulate and characterize 5-FU–loaded PLGA nanoparticles and evaluate their in vitro performance. 5-FU–loaded PLGA nanoparticles were prepared using the double emulsion solvent evaporation method. The nanoparticles were characterized by particle size, polydispersity index, zeta potential and SEM. Drug encapsulation efficiency, loading capacity and in vitro drug release studies were conducted. The formulated nanoparticles exhibited sizes within the nanoscale range with irregular morphology and successful incorporation of 5-FU within the PLGA matrix. The successful formulation and characterization of 5-FU–loaded PLGA nanoparticles highlight their potential as a controlled drug delivery system. These findings provide a foundation for future studies involving biological evaluation and targeted therapeutic applications.","abstract_has_math":false,"creators":["Yandapalli, Kavya"],"institution":null,"degree_name":"Pharmaceutical Sciences","degree_level":"Thesis","degree_discipline":"School of Pharmacy","degree_department":null,"school":null,"contributors":["Dr. Cynthia Jones","Dr. Michael Hambuchen","Dr. Timothy Long"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:58:30Z","subjects":["Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences","Non-Alcoholic Fatty Liver Disease (NAFLD)","PLGA nanoparticles","double emulsion solvent evaporation method5-Fluorouracil"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/2059","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/2059","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-3064","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. Cynthia Jones","Dr. Michael Hambuchen","Dr. Timothy Long"]},{"key":"dc:creator","label":"Author","values":["Yandapalli, Kavya"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2026-04-22T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2026-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["School of Pharmacy"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Pharmaceutical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences","Non-Alcoholic Fatty Liver Disease (NAFLD)","PLGA nanoparticles","double emulsion solvent evaporation method5-Fluorouracil"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/2059"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive metabolic disorder characterized by excessive lipid accumulation in hepatocytes and chronic inflammation. Nanoparticle-based drug delivery systems offer a promising strategy to enhance therapeutic efficacy while minimizing systemic toxicity. The objective of this study is to formulate and characterize 5-FU–loaded PLGA nanoparticles and evaluate their in vitro performance. 5-FU–loaded PLGA nanoparticles were prepared using the double emulsion solvent evaporation method. The nanoparticles were characterized by particle size, polydispersity index, zeta potential and SEM. Drug encapsulation efficiency, loading capacity and in vitro drug release studies were conducted. The formulated nanoparticles exhibited sizes within the nanoscale range with irregular morphology and successful incorporation of 5-FU within the PLGA matrix. The successful formulation and characterization of 5-FU–loaded PLGA nanoparticles highlight their potential as a controlled drug delivery system. These findings provide a foundation for future studies involving biological evaluation and targeted therapeutic applications."]},{"key":"dc:title","label":"Title","values":["Development and in vitro characterization of 5-Fluorouracil–loaded PLGA nanoparticles for controlled drug delivery"]}]}],"canonical_facts":{"dc:contributor":["Dr. Cynthia Jones","Dr. Michael Hambuchen","Dr. Timothy Long"],"dc:creator":["Yandapalli, Kavya"],"dc:date.available":["2026-04-22T07:00:00Z"],"dc:date.created":["2026-01-01T08:00:00Z"],"dc:description.abstract":["Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive metabolic disorder characterized by excessive lipid accumulation in hepatocytes and chronic inflammation. Nanoparticle-based drug delivery systems offer a promising strategy to enhance therapeutic efficacy while minimizing systemic toxicity. The objective of this study is to formulate and characterize 5-FU–loaded PLGA nanoparticles and evaluate their in vitro performance. 5-FU–loaded PLGA nanoparticles were prepared using the double emulsion solvent evaporation method. The nanoparticles were characterized by particle size, polydispersity index, zeta potential and SEM. Drug encapsulation efficiency, loading capacity and in vitro drug release studies were conducted. The formulated nanoparticles exhibited sizes within the nanoscale range with irregular morphology and successful incorporation of 5-FU within the PLGA matrix. The successful formulation and characterization of 5-FU–loaded PLGA nanoparticles highlight their potential as a controlled drug delivery system. These findings provide a foundation for future studies involving biological evaluation and targeted therapeutic applications."],"dc:identifier":["https://mds.marshall.edu/etd/2059"],"dc:subject":["Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences","Non-Alcoholic Fatty Liver Disease (NAFLD)","PLGA nanoparticles","double emulsion solvent evaporation method5-Fluorouracil"],"dc:title":["Development and in vitro characterization of 5-Fluorouracil–loaded PLGA nanoparticles for controlled drug delivery"],"thesis:degree_discipline":["School of Pharmacy"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Pharmaceutical Sciences"]},"updated_at":"2026-11-21T19:58:30Z"}